Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Joe S Pack who wrote (7420)	4/16/1999 2:19:00 PM
From: Tunica Albuginea	Read Replies (1) \| Respond to of 9523

Nat Nithi, I think that you are missing the point. It is clear that the the PRICE APPRECIATION of PFE from ~ $50 in 2/96 to the present $147 was 90% due to Viagra Message 1015263 Same for their exorbitant PE. Well that growth rate ain't there. Trovan will soon develop resistance like everything else; too expensive Lipitor good but WLA I think wants more of the profits ( it's WLA's drug remember? Not PFE's ) Celebrex new but may I have doubts it's pricey and long term safety will be borne out. We have to wait results for all new drugs. Celebrex is made by Searle and Lipitor by WLA. So that PFE's " famous pipeline of reserch is a lot of blue smoke and mirrors IMHO. All we got out of the os Viagra which is now failing, and Trovan which will soon have 6 competitors. Yes, for the last 3 years, PFE's price increase was due to one trick, Viagra. TA ======================================================== To: +John Wasikowski (107 ) From: +Steve Bogart Tuesday, Mar 18 1997 4:28PM ET Reply # of 7421 From Briefing.Com ================ 14:55 ET ****** PFIZER INC (PFE) 92 3/8 -1/4. Though issue is failing to gain ground on Merrill Lynch's upgrade, the stock is in fact benefitting from the move. On a day that has seen drug sector stocks retreat, Bristol Myers (BMY 65 1/2 -2 1/8), Warner-Lambert (WLA 87 1/4 -1 1/8), Rhone-Poulenc (RPR 74 5/8 -1 3/8); this issue is doing a fair job of holding onto yesterday's 1 1/2 points gain. This morning, Merrill Lynch analyst Steve Tighe raised his long-term opinion on this stock to "buy" from "accumulate" and set a 12-month price target of $107 a share. However, the analyst did not budge on his near-term rating of "accumulate," as his positive view is based largely on products still in development.The primary product Tighe is touting is the company's Viagra drug to treat male erectile dysfunction, which the analyst believes will be a large seller in a market that is much larger than was originally projected. He expects Pfizer to file a New Drug Application for Viagra in the second half of 1997. Factoring in the prospects of the drug, Tighe expects the company's 5-year growth rate to accelerate to 18% from a previous rate of 15%. For fiscal years 1997 and 1998, the Merrill analyst estimates earnings of $3.49 and $4.08 a share, respectively.